Midatech’s management is supported by a strong Board of Directors composed of individuals from various industries as well as academia. The breadth and depth of its members’ experience in medicine, pharmaceuticals, finance, strategy and general management is instrumental in providing advice and leadership to the Company.
Mr Stahel has approximately 40 years of experience in the pharmaceutical industry, of which around 20 years were spent at Chief Executive and Board level in public (United Kingdom, Switzerland and United States) and private life science companies registered in Europe, the United States and Asia. Mr Stahel joined Shire as CEO in 1994 following a 27-year career at Wellcome plc (now GSK). He is currently the Non-executive Chairman of Connexios Life Sciences Pvt Ltd and Ergomed PLC, and previously the Non-executive Chairman of EUSA Pharma, Cosmos Pharmaceuticals SpA, PowderMed Ltd and Newron Pharmaceuticals SpA.
Mr Brown is the CEO and founding member of Brown Equity Partners, LLC. He has served on the Board of Directors of more than 40 companies during his 28 years in the investment industry. Mr Brown was a Senior Vice President with Bank of America Venture Capital and has also been Chairman of the Board of ten companies in both the public and private sectors. Mr Brown graduated Summa Cum Laude and was a mathematics major from Willamette University in 1983. He also graduated from the Stanford University Graduate School of Business where he earned his MBA in 1987.
Keith J. Kendall
Co- President and Chief Operating Officer of MonoSol Rx; former Vice President and Managing Director for Hewlett Packard Financial Services; former President of AT&T Credit Corporation and NCR Credit Corporation.
Mr Luzi is a director in Bain & Company’s London office, and head of the firm’s EMEA Telecommunications, Media and Technology practice. He is a retired member of Bain & Company’s Board of Directors Committee. Prior to joining Bain & Company, Mr Luzi worked in management positions with Pirelli, Agusta, and the Italian Trade Commission. He earned his MBA from INSEAD and a degree in economics, with honours, from the University of Rome.
Mr Protopapa is the founder and Managing Partner of Ippon Capital and is the co-founder and CEO of Spacecode Holdings. He also serves on the advisory board of Socure Inc., an internet security software company. Mr Protopapa qualified as an accountant at KPMG where we worked as an audit supervisor and previously he was Chief Financial Officer of Steinmetz Diamond Group.
Non-executive director of two banks; Former partner at BDO Stoy Hayward; advisor to the board of a US gaming and entertainment company.
Sijmen de Vries
Dr de Vries has extensive senior level experience in both the pharmaceutical and biotechnology industry. He is currently CEO and CFO of Pharming group N.V., the Euronext-listed pharmaceutical company. Dr de Vries was previously CEO of both Switzerland-based 4-Antibody and Morphochem AG, and prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr de Vries holds an MD degree from the University of Amsterdam and a MBA in General Management from Ashridge Management College (UK).
Chief Executive Officer
See Management Team